BiotechTube
Home/Kyowa Hakko Kirin/Masashi Miyamoto
MM

Masashi Miyamoto

Representative Director, Chairman of the Board

Kyowa Hakko Kirin

Roles

Representative Director, Chairman of the BoardatKyowa Hakko Kirin
Representative Director, Chairman of the BoardatKyowa Kirin

Therapeutic Areas

Bone & MineralHematologic MalignanciesRare Diseases

Kyowa Hakko Kirin Pipeline

DrugIndicationPhase
Crysvita (burosumab)X-Linked Hypophosphatemia (XLH), Tumor-Induced Osteomalacia (TIO)Marketed
Poteligeo (mogamulizumab)Cutaneous T-Cell Lymphoma (CTCL), Adult T-Cell Leukemia/Lymphoma (ATL)Marketed
Libmeldy (atidarsagene autotemcel)Metachromatic Leukodystrophy (MLD)Marketed
Orchard HSC-GT ProgramsWiskott-Aldrich Syndrome, MPS-IH, Beta-ThalassemiaPhase 1/2
KW-6356Parkinson's DiseasePhase 3
KHK4083Atopic DermatitisPhase 3
KHK2455Ulcerative Colitis / Autoimmune DiseasesPhase 2
ASP2138 (KHK4008)Solid Tumors (CLDN18.2+)Phase 1/2

Leadership Team at Kyowa Hakko Kirin

AM
Abdul Mullick
Representative Director, President and Chief Executive Officer
View full Kyowa Hakko Kirin profile